As Teva Pharmaceutical Inds LTD (TEVA) Share Value Declined, Davidson D A & Company Has Decreased Its Stake by $3.43 Million; As Synaptics (SYNA) Shares Declined, Crosslink Capital Cut Its Holding by $3.84 Million

January 18, 2018 - By Adrian Erickson

Seymour Sy Kaufman decreased its stake in Synaptics (SYNA) by 45.42% based on its latest 2017Q3 regulatory filing with the SEC. Crosslink Capital Inc sold 98,394 shares as the company’s stock declined 5.40% while stock markets rallied. The hedge fund run by Seymour Sy Kaufman held 118,246 shares of the edp services company at the end of 2017Q3, valued at $4.63M, down from 216,640 at the end of the previous reported quarter. Crosslink Capital Inc who had been investing in Synaptics for a number of months, seems to be less bullish one the $1.50B market cap company. The stock decreased 5.84% or $2.735 during the last trading session, reaching $44.085. About 645,248 shares traded. Synaptics Incorporated (NASDAQ:SYNA) has declined 12.49% since January 18, 2017 and is downtrending. It has underperformed by 29.19% the S&P500.

Thomas Lenox Kempner decreased its stake in Teva Pharmaceutical Inds Ltd (TEVA) by 75.73% based on its latest 2017Q3 regulatory filing with the SEC. Davidson D A & Company sold 201,758 shares as the company’s stock declined 15.11% while stock markets rallied. The hedge fund run by Thomas Lenox Kempner held 64,663 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $1.14M, down from 266,421 at the end of the previous reported quarter. Davidson D A & Company who had been investing in Teva Pharmaceutical Inds Ltd for a number of months, seems to be less bullish one the $21.41B market cap company. The stock decreased 1.91% or $0.41 during the last trading session, reaching $21.07. About 14.49 million shares traded. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has declined 41.70% since January 18, 2017 and is downtrending. It has underperformed by 58.40% the S&P500.

Analysts await Teva Pharmaceutical Industries Limited (NYSE:TEVA) to report earnings on February, 12. They expect $0.75 EPS, down 44.85% or $0.61 from last year’s $1.36 per share. TEVA’s profit will be $762.00M for 7.02 P/E if the $0.75 EPS becomes a reality. After $0.95 actual EPS reported by Teva Pharmaceutical Industries Limited for the previous quarter, Wall Street now forecasts -21.05% negative EPS growth.

Davidson D A & Company, which manages about $9.65 billion and $5.10B US Long portfolio, upped its stake in F5 Networks Inc (NASDAQ:FFIV) by 4,209 shares to 21,637 shares, valued at $2.61 million in 2017Q3, according to the filing. It also increased its holding in Ishares Tr (QUAL) by 16,079 shares in the quarter, for a total of 291,411 shares, and has risen its stake in Calamos Dynamic Conv & Incom.

Among 33 analysts covering Teva Pharma (NYSE:TEVA), 9 have Buy rating, 7 Sell and 17 Hold. Therefore 27% are positive. Teva Pharma had 128 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Neutral” rating given on Friday, February 10 by Mizuho. The rating was initiated by Wells Fargo with “Outperform” on Friday, February 19. The firm has “Sell” rating by RBC Capital Markets given on Monday, October 30. The stock has “Hold” rating by Cowen & Co on Wednesday, October 4. The firm earned “Outperform” rating on Tuesday, July 21 by Leerink Swann. On Wednesday, November 16 the stock rating was downgraded by Jefferies to “Hold”. The rating was upgraded by Oppenheimer on Friday, September 2 to “Outperform”. JP Morgan downgraded the stock to “Underweight” rating in Monday, November 13 report. The company was upgraded on Monday, July 18 by HSBC. The rating was upgraded by Credit Suisse on Monday, October 31 to “Outperform”.

Analysts await Synaptics Incorporated (NASDAQ:SYNA) to report earnings on January, 25. They expect $0.69 earnings per share, down 34.91% or $0.37 from last year’s $1.06 per share. SYNA’s profit will be $23.48 million for 15.97 P/E if the $0.69 EPS becomes a reality. After $0.55 actual earnings per share reported by Synaptics Incorporated for the previous quarter, Wall Street now forecasts 25.45% EPS growth.

Investors sentiment increased to 1.06 in Q3 2017. Its up 0.08, from 0.98 in 2017Q2. It improved, as 40 investors sold SYNA shares while 69 reduced holdings. 34 funds opened positions while 81 raised stakes. 34.89 million shares or 3.70% more from 33.64 million shares in 2017Q2 were reported. Bridgeway holds 0.01% of its portfolio in Synaptics Incorporated (NASDAQ:SYNA) for 18,700 shares. 218 were accumulated by Weaver C Barksdale Associates. Willingdon Wealth Mgmt stated it has 0% in Synaptics Incorporated (NASDAQ:SYNA). State Board Of Administration Of Florida Retirement owns 0% invested in Synaptics Incorporated (NASDAQ:SYNA) for 18,991 shares. Jpmorgan Chase And owns 277,975 shares for 0% of their portfolio. Quantbot Tech LP invested in 16,461 shares. Group One Trading LP reported 14,354 shares or 0.01% of all its holdings. Manufacturers Life Insurance Company The invested in 0% or 74,434 shares. Livforsakringsbolaget Skandia Omsesidigt has invested 0.08% in Synaptics Incorporated (NASDAQ:SYNA). Kempen Capital Nv owns 82,216 shares. Walleye Trading Ltd Llc has invested 0.01% in Synaptics Incorporated (NASDAQ:SYNA). Soros Fund Mngmt Ltd Llc has invested 0.45% in Synaptics Incorporated (NASDAQ:SYNA). Prudential Finance Incorporated owns 718,646 shares for 0.05% of their portfolio. Citigroup Inc accumulated 9,887 shares. Aperio Limited Com owns 0% invested in Synaptics Incorporated (NASDAQ:SYNA) for 6,686 shares.

Among 16 analysts covering Synaptics Inc (NASDAQ:SYNA), 9 have Buy rating, 0 Sell and 7 Hold. Therefore 56% are positive. Synaptics Inc had 66 analyst reports since August 3, 2015 according to SRatingsIntel. On Thursday, March 16 the stock rating was upgraded by Northland Capital to “Outperform”. Oppenheimer maintained Synaptics Incorporated (NASDAQ:SYNA) rating on Friday, August 4. Oppenheimer has “Sell” rating and $4500 target. The firm earned “Sell” rating on Monday, August 21 by Oppenheimer. Cowen & Co maintained Synaptics Incorporated (NASDAQ:SYNA) rating on Wednesday, December 13. Cowen & Co has “Buy” rating and $58.0 target. The stock of Synaptics Incorporated (NASDAQ:SYNA) earned “Buy” rating by Mizuho on Thursday, October 13. Oppenheimer maintained the stock with “Sell” rating in Tuesday, June 13 report. The company was downgraded on Wednesday, January 20 by Oppenheimer. The firm earned “Buy” rating on Friday, January 29 by Needham. Mizuho maintained Synaptics Incorporated (NASDAQ:SYNA) rating on Friday, July 31. Mizuho has “Buy” rating and $105 target. Mizuho maintained the shares of SYNA in report on Tuesday, June 13 with “Buy” rating.

Since January 12, 2018, it had 0 insider purchases, and 1 sale for $1.00 million activity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: